| Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers X Chai, TM Friebel, CF Singer, DG Evans, HT Lynch, C Isaacs, JE Garber, ... Breast cancer research and treatment 148, 397-406, 2014 | 75 | 2014 |
| RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction X Chai, S Domchek, N Kauff, T Rebbeck, J Chen Journal of the National Cancer Institute 107 (9), djv217, 2015 | 35 | 2015 |
| Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan S Wakase, T Teshima, J Zhang, Q Ma, Y Watanabe, H Yang, CZ Qi, ... Transplantation and Cellular Therapy 27 (3), 241. e1-241. e11, 2021 | 22 | 2021 |
| Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan S Wakase, T Teshima, J Zhang, Q Ma, T Fujita, H Yang, X Chai, CZ Qi, ... Transplantation and Cellular Therapy 27 (6), 506. e1-506. e10, 2021 | 18 | 2021 |
| Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma RT Maziarz, J Zhang, H Yang, X Chai, C Yuan, E Schwarz, M Jakovac, ... Blood advances 6 (8), 2536-2547, 2022 | 17 | 2022 |
| Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a US hospital’s perspective H Yang, Y Hao, CZ Qi, X Chai, EQ Wu Journal of Managed Care & Specialty Pharmacy 26 (8), 971-980, 2020 | 12 | 2020 |
| Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women LJ Zhang, VY Shin, X Chai, A Zhang, TL Chan, ES Ma, TR Rebbeck, ... Oncotarget 9 (38), 25025, 2018 | 12 | 2018 |
| Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective H Yang, Y Hao, X Chai, CZ Qi, EQ Wu Journal of Medical Economics 23 (9), 1016-1024, 2020 | 11 | 2020 |
| Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for … KW Pratz, X Chai, J Xie, L Yin, X Nie, M Montez, E Iantuono, L Downs, ... Pharmacoeconomics 40 (8), 777-790, 2022 | 7 | 2022 |
| P1111: comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel in relapsed/refractory follicular lymphoma M Dickinson, J Martinez-Lopez, E Jousseaume, C Anjos, H Yang, X Chai, ... Hemasphere 6, 1001-1002, 2022 | 7 | 2022 |
| Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis K Guinan, K Mathurin, Y Au, AC Schuh, CN Bui, X Chai, J Lachaine Current Oncology 29 (10), 7524-7536, 2022 | 3 | 2022 |
| Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive … KW Pratz, X Chai, J Xie, L Yin, X Nie, M Montez, E Iantuono, L Downs, ... Blood 138, 112, 2021 | 3 | 2021 |
| The risk reduction of accidental exposure-related systemic allergic reactions extrapolated based on food challenge data after 1 year of peanut oral immunotherapy S Yu, A Smith, S Hass, E Wu, X Chai, J Zhou, R Ayyagari, JS Liu, ... Advances in Therapy 38, 4321-4332, 2021 | 3 | 2021 |
| cost-effectiveness analysis of lenalidomide for maintenance therapy after autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) patients: a United … ZY Zhou, K Parikh, X Chai, A Rokito, C Udeze, J Xie, A Agarwal Blood 132, 3535, 2018 | 3 | 2018 |
| POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy K Pratz, J Lachaine, HS Suh, X Li, AC Schuh, X Chai, J Xie, L Yin, CN Bui Value in Health 25 (1), S230, 2022 | 2 | 2022 |
| Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective H Yang, Y Hao, X Chai, CZ Qi, EQ Wu Blood 134, 3419, 2019 | 2 | 2019 |
| Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma M Dickinson, J Martinez-Lopez, E Jousseaume, H Yang, X Chai, C Xiang, ... Leukemia & Lymphoma 65 (3), 323-332, 2024 | 1 | 2024 |
| Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy M Choi, J Song, CN Bui, E Ma, X Chai, L Yin, KA Betts, T Kapustyan, ... Journal of Managed Care & Specialty Pharmacy 28 (9), 980-988, 2022 | 1 | 2022 |
| Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective H Yang, Y Hao, CZ Qi, X Chai, EQ Wu Blood 134, 4723, 2019 | 1 | 2019 |
| EE46 Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective K Guinan, K Mathurin, Y Au, AC Schuh, CN Bui, X Chai, J Lachaine Value in Health 25 (7), S344, 2022 | | 2022 |
